Aktuelles Aktuelles  
Source:  >> Stuttgart Region Economic Development Corporation
Jun 06, 2005
Blue Blood for Tumor Therapy
There is a living pharmacy dormant inside the inconspicuous Californian keyhole snail “Meguratha crenulata”. The cancer combating active agent “Keyhole limpet hemocyanin (KLH)” can be extracted from the lymph of this palm-sized marine snail; this substance is irreplaceable for bladder carcinoma therapy. For the Fellbach-based biosyn GmbH, which has specialized in the manufacture of medication for cancer and intensive-care medicine, this “tumor therapy from the ocean” is one of its most important projects. In the 20th year of its existence, the company globally comprises a staff of more than 80 employees and is among the leading medium-scale pharmaceutical companys.

To extract the raw material for the anti-cancer active agent “Immunocyanin” from the Meguratha crenulata, biosyn maintained its own sea water aquarium in Fellbach for a very long time. The snails were kept there under conditions simulating those in the Pacific. To obtain the precious blue blood – the color comes from the high copper content – the snails were punctured under cold anesthetic and placed back in the trough undamaged. This step is now carried out in the laboratories of the Californian subsidiary biosyn Corporation in Carlsbad. In Fellbach, the snail lymph is bio-technologically cleaned and prepared. The aim of the bio-technology pioneers now is the genetically engineered manufacture of the active agent Immunocyanin.

Immunocyanin as a medication is already an approved drug in several countries under the trademark Immucothel, and verifiable results are being reported from Holland and Austria. There, Immucothel is used to prevent the growth of new bladder tumors after operations. “biosyn is the only supplier in the world that can manufacture this highly purified glycoprotein in the quality that is required for clinical use”, says Ortwin Kottwitz, Managing Directory of biosyn Arzneimittel GmbH. “Nonetheless, we are still waiting for approval in Germany.”

Apart from 30 other highly promising preparations, the medicament “Fiblaferon” has been part of biosyn’s product range for many years. It is the only medication available in Germany that is effective against certain carcinoma in the respiratory tracts as well as against difficult-to-control viral infections like shingles, meningitis or inner ear inflammations. It was also approved for the treatment of the lung sickness SARS.

The dual principle of curing the sickness and supporting the self-healing mechanisms has top priority at biosyn. Another key to its success is the purposeful focus on the global market. Thus, the first office in a foreign country was founded as early as in 1985 in Vienna; Intersyn AG in Switzerland followed in 1993. The biosyn Corporation in California has been in existence since 1995; in Europe and South America, biosyn has licensees who will market the products from Fellbach according to their country-specific approvals.

The Stuttgart region
The Stuttgart region has long been known as the center of Europe’s automotive and industrial machinery industry. More recently, Eurostat, the European Statistical Office, has labeled it “the high-tech capital of Europe”. It is the home of global companies including DaimlerChrysler, Porsche and Bosch and also leading universities and private research institutes. It is a region of 2.6 million people and Germany’s lowest unemployment rate, highest export ratio and highest number of patents per capita.

Additional information is available at www.investor-companion.de

The Stuttgart Region Economic Development Corporation works to provide favorable business conditions and assist all companies located in or considering the region, large and small. Additional information is available at www.wrs-gmbh.de or from Arndt Siepmann at the agency’s U.S. office, northamerica@region-stuttgart.de.
In our forthcoming press releases we will introduce you to companies, institutions and personalities whose ideas or products are exemplary for the competitiveness and the innovative power of this region. The publishing of our texts is complimentary and should you choose to do so, we would be grateful if you could send us a copy.



Economy, Science
Author: > Madeja
>> Stuttgart Region Economic Development Corporation
The network for university and research institution spin-offs

  ^ top      

> Feedback | > Legal notice